Researchers should consult primary literature on Ipamorelin and CJC-1295 (modified GRF 1-29) for protocol-specific concentrations
The optimal dosage range for most users falls between 20-50 mcg per day administered via subcutaneous or intramuscular injection
Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability

IGF-1R Binding and Downstream Signalling IGF-1 LR3 remains a full agonist of the IGF-1 receptor, with very low affinity for IGFBPs making it more potent than unmodified IGF-1 in cell culture and pre-clinical models
Frequently asked questions Where is my order, and how can I track it